Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2010

01-02-2010 | Editorial

Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?

Author: Rodney J Scott

Published in: Breast Cancer Research | Issue 1/2010

Login to get access

Abstract

Genetic differences between individuals have been predicted to account for disparate outcomes in patients diagnosed with cancer. The search for genetic determinants has been ongoing for a considerable amount of time and it is only now that insights have been gained into which polymorphisms are most likely to be important in determining not only disease likelihood but also outcome. The quest to be able to accurately predict patient outcomes in breast cancer may now be a step closer as increased sample size is leading to more robust statistical analysis and a better understanding of molecular mechanisms of disease are forthcoming.
Literature
1.
Schmidt Mk, Tommiska J, Broeks A, van Leeuwen FE, van't Veer LJ, Pharoah PDP, Easton DF, Shah M, Humphreys M, Dörk T, Reincke SA, Fagerholm R, Blomqvist C, Nevanlinna H: Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res. 2009, 11: R89-10.1186/bcr2460.CrossRefPubMedPubMedCentral
2.
Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003, 33: 357-365. 10.1038/ng1093.CrossRefPubMed
3.
Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang S-J, Strong LC, Lozano G, Levine AJ: A single nucleotide polypmorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004, 119: 591-602. 10.1016/j.cell.2004.11.022.CrossRefPubMed
4.
Cox DG, Deer D, Guo Q, Tworoger SS, Hankinson SE, Hunter DJ, De Vivo I: The p53 Arg72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses' health study. Cancer Causes Control. 2007, 18: 621-625. 10.1007/s10552-007-9004-x.CrossRefPubMed
5.
Campbell IG, Eccles DM, Choon DYH: No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett. 2006, 240: 195-197. 10.1016/j.canlet.2005.09.003.CrossRefPubMed
6.
Idbaih A, Boisselier B, Marie Y, Sanson M, Hallani SE, Crinière E, Fourtassi M, Paris S, Carpentier C, Rousseau A, Mokhtari K, Combadière C, Laigle-Donadey F, Delattre J-Y: Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. Brain Res. 2008, 1198: 16-20. 10.1016/j.brainres.2008.01.027.CrossRefPubMed
7.
Alhopuro P, Ylisaukko-oja SK, Koskinen WJ, Bono P, Arola J, Järvinen HJ, Mecklin J-P, Atula T, Kontio R, Mäkitie AA, Suominen S, Leivo I, Vahteristo P, Aaltonen L-M, Asltonen LA: The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet. 2005, 42: 694-698. 10.1136/jmg.2005.031260.CrossRefPubMedPubMedCentral
8.
Schmidt MK, reincke S, Broeks A, Braaf LM, Hogervorst FBL, Tollenaar RAEM, Johnson N, Fletcher O, Peto J, Tommiska J, Blomqvist C, Nevanlinna HA, Healey CS, Dunning AM, Pharoah PDP, Easton DF, Dörk T, Van't Veer LJ, on behalf of the Breast Cancer Association Consortium: Do MDM2 SNP309 and TP53R72P interact in breast cancer susceptibility? A large pooled seires from the breast cancer association consortium. Cancer Res. 2007, 67: 9584-9590. 10.1158/0008-5472.CAN-07-0738.CrossRefPubMed
9.
Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, Chompret A, Bressac-de Paillerets, Stoppa-Lyonnet D, Bonaiti-Pellie C, Frebourg T: Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet. 2006, 43: 531-533. 10.1136/jmg.2005.037952.CrossRefPubMed
10.
Ruijs MWG, Schmidt MK, Nevanlinna H, Tommiska J, Aittomaki K, Pruntel R, Verhoef S, van't Veer LJ: The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet. 2007, 15: 110-114. 10.1038/sj.ejhg.5201715.CrossRefPubMed
11.
Do TN, Ucisik-Akkaya E, davis CF, Morrison BA, Dorak MT: TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility. Cancer Genet Cytogenet. 2009, 195: 31-36. 10.1016/j.cancergencyto.2009.05.009.CrossRefPubMed
12.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Rijn van de M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brwon PO, Botstein D, Lønning PE, Børresen-Dale A-L: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001, 98: 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral
13.
Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EMJJ, Atkins D, Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005, 365: 671-679.CrossRefPubMed
14.
Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DSA, Nobel AB, van't Veer LJ, Perou CM: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006, 355: 560-569. 10.1056/NEJMoa052933.CrossRefPubMed
Metadata
Title
Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?
Author
Rodney J Scott
Publication date
01-02-2010
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2010
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2474

Other articles of this Issue 1/2010

Breast Cancer Research 1/2010 Go to the issue

Research article

Risk of breast cancer among daughters of mothers with diabetes: a population-based cohort study

Viewpoint

Tracking the genomic evolution of breast cancer metastasis

Research article

Familial relative risks for breast cancer by pathological subtype: a population-based cohort study

Research article

(-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma

Editorial

The more things change ... the more things change: developmental plasticity of tumor-initiating mammary epithelial cells

Research article

Type I gamma phosphatidylinositol phosphate kinase modulates invasion and proliferation and its expression correlates with poor prognosis in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits